Nexien Biopharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nexien Biopharma Inc (NXEN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Nexien Biopharma Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nexien Biopharma Inc | - | - | - | Yes |
| Competitors combined (107) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NXEN Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 3 | Abcellera Biologics Inc | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Xencor Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nexien Biopharma Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Nexien Biopharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Nexien Biopharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Nexien Biopharma Inc |
0.01 | - |
 Eli Lilly And Company |
1,278,223.12 | 86,462.00 |
 Johnson and Johnson |
694,227.07 | 99,335.00 |
 Abbvie Inc |
521,818.56 | 66,014.00 |
 Merck and Co Inc |
362,966.50 | 66,569.00 |
 Novartis Ag |
313,288.75 | 56,674.00 |
| SUBTOTAL | 5,113,008.64 | 856,088.69 |
Sign in to see all competitors of Nexien Biopharma Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nexien Biopharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nexien Biopharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Nexien Biopharma Inc .
Nexien Biopharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nexien Biopharma Inc | 0 | - | -14,468 |
| Eli Lilly And Company | 1,278,223 | 1,729,240 | 551,594 |
| Johnson and Johnson | 694,227 | 705,504 | 114,311 |
| Abbvie Inc | 521,819 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,967 | 887,587 | 42,267 |
| Novartis Ag | 313,289 | 752,973 | 185,566 |
| PEERS TOTAL | 5,113,009 | 920,220 | 127,156 |
Sign in to see all peers for Nexien Biopharma Inc .
Nexien Biopharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Abbott Laboratories | Non-US 57.70 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Nexien Biopharma Inc .
Nexien Biopharma Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Nexien Biopharma Inc's industry classification, broader than the peer set above. Market cap in millions of $.Nexien Biopharma Inc ranks #0 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 995, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,278,652 | 24.03 % |
| 2 | Johnson and Johnson | 691,817 | 13.00 % |
| 3 | Abbvie Inc | 521,524 | 9.80 % |
| 4 | Merck and Co Inc | 362,966 | 6.82 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Nexien Biopharma Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Nexien Biopharma Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-11.
Nexien Biopharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | -1.7x | 4.2x | -6.0x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.73 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Nexien Biopharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | - | -179.67 % | -870.38 % | -5,267.60 % | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nexien Biopharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 995 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Nexien Biopharma Inc's dedicated Suppliers and Customers pages, not here.
Nexien Biopharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (45.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-21.7% annualized).
Methodology: see Methodology: SWOT Analysis.
Nexien Biopharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nexien Biopharma Inc | 0.01 | 0.01 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Nexien Biopharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nexien Biopharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nexien Biopharma Inc | Q1 2025 | - | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +10.1 % | +0.4 % |
Sign in to see all peers for Nexien Biopharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nexien Biopharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nexien Biopharma Inc | Q1 2025 | - | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Nexien Biopharma Inc .
Nexien Biopharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nexien Biopharma Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Nexien Biopharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nexien Biopharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nexien Biopharma Inc | - | - |
| Eli Lilly And Company | 46.45 | 14.78 |
| Johnson and Johnson | 42.89 | 6.99 |
| Abbvie Inc | 50.69 | 7.90 |
| Merck and Co Inc | 118.51 | 5.45 |
| Novartis Ag | 22.40 | 5.53 |
| PEERS AVERAGE | 43.22 | 5.97 |
Sign in to see all peers for Nexien Biopharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.